Lung Disease Therapeutics Market (Disease Type: Asthma, Chronic Obstructive Pulmonary Disease, Lung Cancer, and Other Lung Diseases) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
Lung Disease Therapeutics Market – Scope of Report
TMR’s report on the global lung disease therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global lung disease therapeutics market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lung disease therapeutics market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the lung disease therapeutics market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global lung disease therapeutics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global lung disease therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global lung disease therapeutics market.
The report delves into the competitive landscape of the global lung disease therapeutics market. Key players operating in the global lung disease therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global lung disease therapeutics market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market lung disease therapeutics.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
- Industry Sources:
- WorldWideScience.org
- Elsevier, Inc.
- National Institutes of Health (NIH)
- PubMed
- NCBI
- Department of Health Care Service
- Trade Data Sources
- Trade Map
- UN Comtrade
- Trade Atlas
- Company Information
- OneSource Business Browser
- Hoover’s
- Factiva
- Bloomberg
- Mergers & Acquisitions
- Thomson Mergers & Acquisitions
- MergerStat
- Profound
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
- 1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
- 2. Assumptions and Research Methodology
- 3. Executive Summary: Global Lung Disease Therapeutics Market
- 4. Market Overview
- 4.1. Introduction
- 4.1.1. Segment Definition
- 4.1.2. Industry Evolution / Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Lung Disease Therapeutics Market Analysis and Forecast, 2017–2031
- 5. Key Insights
- 5.1. Technological Advancements
- 5.2. Drug Pipeline Analysis
- 5.3. Disease Prevalence & Incidence Rate Globally With Key Countries
- 5.4. Regulatory Scenario by Region/Globally
- 5.5. COVID-19 Impact Analysis
- 6. Global Lung Disease Therapeutics Market Analysis and Forecast, by Disease Type
- 6.1. Introduction & Definition
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Disease Type, 2017–2031
- 6.3.1. Asthma
- 6.3.2. Chronic Obstructive Pulmonary Disease (COPD)
- 6.3.3. Lung Cancer
- 6.3.4. Others
- 6.4. Market Attractiveness Analysis, by Disease Type
- 7. Global Lung Disease Therapeutics Market Analysis and Forecast, by Drug Class
- 7.1. Introduction & Definition
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Drug Class, 2017–2031
- 7.3.1. Corticosteroids
- 7.3.2. Bronchodilator Medications
- 7.3.3. Mucolytics
- 7.3.4. Antimicrobial Medications
- 7.3.5. Others
- 7.4. Market Attractiveness Analysis, by Drug Class
- 8. Global Lung Disease Therapeutics Market Analysis and Forecast, by Distribution Channel
- 8.1. Introduction & Definition
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast, by Distribution Channel, 2017–2031
- 8.3.1. Hospital Pharmacies
- 8.3.2. Retail Pharmacies
- 8.3.3. Online Pharmacies
- 8.4. Market Attractiveness Analysis, by Distribution Channel
- 9. Global Lung Disease Therapeutics Market Analysis and Forecast, by Region
- 9.1. Key Findings
- 9.2. Market Value Forecast, by Region, 2017–2031
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
- 9.3. Market Attractiveness Analysis, by Region
- 10. North America Lung Disease Therapeutics Market Analysis and Forecast
- 10.1. Introduction
- 10.1.1. Key Findings
- 10.2. Market Value Forecast, by Disease Type, 2017–2031
- 10.2.1. Asthma
- 10.2.2. Chronic Obstructive Pulmonary Disease (COPD)
- 10.2.3. Lung Cancer
- 10.2.4. Others
- 10.3. Market Value Forecast, by Drug Class, 2017–2031
- 10.3.1. Corticosteroids
- 10.3.2. Bronchodilator Medications
- 10.3.3. Mucolytics
- 10.3.4. Antimicrobial Medications
- 10.3.5. Others
- 10.4. Market Value Forecast, by Distribution Channel, 2017–2031
- 10.4.1. Hospital Pharmacies
- 10.4.2. Retail Pharmacies
- 10.4.3. Online Pharmacies
- 10.5. Market Value Forecast, by Country, 2017–2031
- 10.5.1. U.S.
- 10.5.2. Canada
- 10.6. Market Attractiveness Analysis
- 10.6.1. By Disease Type
- 10.6.2. By Drug Class
- 10.6.3. By Distribution Channel
- 10.6.4. By Country
- 11. Europe Lung Disease Therapeutics Market Analysis and Forecast
- 11.1. Introduction
- 11.1.1. Key Findings
- 11.2. Market Value Forecast, by Disease Type, 2017–2031
- 11.2.1. Asthma
- 11.2.2. Chronic Obstructive Pulmonary Disease (COPD)
- 11.2.3. Lung Cancer
- 11.2.4. Others
- 11.3. Market Value Forecast, by Drug Class, 2017–2031
- 11.3.1. Corticosteroids
- 11.3.2. Bronchodilator Medications
- 11.3.3. Mucolytics
- 11.3.4. Antimicrobial Medications
- 11.3.5. Others
- 11.4. Market Value Forecast, by Distribution Channel, 2017–2031
- 11.4.1. Hospital Pharmacies
- 11.4.2. Retail Pharmacies
- 11.4.3. Online Pharmacies
- 11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
- 11.5.1. Germany
- 11.5.2. U.K.
- 11.5.3. France
- 11.5.4. Italy
- 11.5.5. Spain
- 11.5.6. Rest of Europe
- 11.6. Market Attractiveness Analysis
- 11.6.1. By Disease Type
- 11.6.2. By Drug Class
- 11.6.3. By Distribution Channel
- 11.6.4. By Country/Sub-region
- 12. Asia Pacific Lung Disease Therapeutics Market Analysis and Forecast
- 12.1. Introduction
- 12.1.1. Key Findings
- 12.2. Market Value Forecast, by Disease Type, 2017–2031
- 12.2.1. Asthma
- 12.2.2. Chronic Obstructive Pulmonary Disease (COPD)
- 12.2.3. Lung Cancer
- 12.2.4. Others
- 12.3. Market Value Forecast, by Drug Class, 2017–2031
- 12.3.1. Corticosteroids
- 12.3.2. Bronchodilator Medications
- 12.3.3. Mucolytics
- 12.3.4. Antimicrobial Medications
- 12.3.5. Others
- 12.4. Market Value Forecast, by Distribution Channel, 2017–2031
- 12.4.1. Hospital Pharmacies
- 12.4.2. Retail Pharmacies
- 12.4.3. Online Pharmacies
- 12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
- 12.5.1. China
- 12.5.2. Japan
- 12.5.3. India
- 12.5.4. Australia & New Zealand
- 12.5.5. Rest of Asia Pacific
- 12.6. Market Attractiveness Analysis
- 12.6.1. By Disease Type
- 12.6.2. By Drug Class
- 12.6.3. By Distribution Channel
- 12.6.4. By Country/Sub-region
- 13. Latin America Lung Disease Therapeutics Market Analysis and Forecast
- 13.1. Introduction
- 13.1.1. Key Findings
- 13.2. Market Value Forecast, by Disease Type, 2017–2031
- 13.2.1. Asthma
- 13.2.2. Chronic Obstructive Pulmonary Disease (COPD)
- 13.2.3. Lung Cancer
- 13.2.4. Others
- 13.3. Market Value Forecast, by Drug Class, 2017–2031
- 13.3.1. Corticosteroids
- 13.3.2. Bronchodilator Medications
- 13.3.3. Mucolytics
- 13.3.4. Antimicrobial Medications
- 13.3.5. Others
- 13.4. Market Value Forecast, by Distribution Channel, 2017–2031
- 13.4.1. Hospital Pharmacies
- 13.4.2. Retail Pharmacies
- 13.4.3. Online Pharmacies
- 13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
- 13.5.1. Brazil
- 13.5.2. Mexico
- 13.5.3. Rest of Latin America
- 13.6. Market Attractiveness Analysis
- 13.6.1. By Disease Type
- 13.6.2. By Drug Class
- 13.6.3. By Distribution Channel
- 13.6.4. By Country/Sub-region
- 14. Middle East & Africa Lung Disease Therapeutics Market Analysis and Forecast
- 14.1. Introduction
- 14.1.1. Key Findings
- 14.2. Market Value Forecast, by Disease Type, 2017–2031
- 14.2.1. Asthma
- 14.2.2. Chronic Obstructive Pulmonary Disease (COPD)
- 14.2.3. Lung Cancer
- 14.2.4. Others
- 14.3. Market Value Forecast, by Drug Class, 2017–2031
- 14.3.1. Corticosteroids
- 14.3.2. Bronchodilator Medications
- 14.3.3. Mucolytics
- 14.3.4. Antimicrobial Medications
- 14.3.5. Others
- 14.4. Market Value Forecast, by Distribution Channel, 2017–2031
- 14.4.1. Hospital Pharmacies
- 14.4.2. Retail Pharmacies
- 14.4.3. Online Pharmacies
- 14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
- 14.5.1. GCC Countries
- 14.5.2. South Africa
- 14.5.3. Rest of MEA
- 14.6. Market Attractiveness Analysis
- 14.6.1. By Disease Type
- 14.6.2. By Drug Class
- 14.6.3. By Distribution Channel
- 14.6.4. By Country/Sub-region
- 15. Competition Landscape
- 15.1. Market Player - Competitive Matrix (by tier and size of companies)
- 15.2. Market Share Analysis, by Company (2021)
- 15.3. Company Profiles
- 15.3.1. GSK
- 15.3.1.1. Company Overview
- 15.3.1.2. Disease Type Portfolio
- 15.3.1.3. SWOT Analysis
- 15.3.1.4. Financial Overview
- 15.3.1.5. Strategic Overview
- 15.3.2. AstraZeneca
- 15.3.2.1. Company Overview
- 15.3.2.2. Disease Type Portfolio
- 15.3.2.3. SWOT Analysis
- 15.3.2.4. Financial Overview
- 15.3.2.5. Strategic Overview
- 15.3.3. Boehringer Ingelheim
- 15.3.3.1. Company Overview
- 15.3.3.2. Disease Type Portfolio
- 15.3.3.3. SWOT Analysis
- 15.3.3.4. Financial Overview
- 15.3.3.5. Strategic Overview
- 15.3.4. Novartis
- 15.3.4.1. Company Overview
- 15.3.4.2. Disease Type Portfolio
- 15.3.4.3. SWOT Analysis
- 15.3.4.4. Financial Overview
- 15.3.4.5. Strategic Overview
- 15.3.5. Vertex Pharmaceuticals
- 15.3.5.1. Company Overview
- 15.3.5.2. Disease Type Portfolio
- 15.3.5.3. SWOT Analysis
- 15.3.5.4. Financial Overview
- 15.3.5.5. Strategic Overview
- 15.3.6. F. Hoffman La Roche
- 15.3.6.1. Company Overview
- 15.3.6.2. Disease Type Portfolio
- 15.3.6.3. SWOT Analysis
- 15.3.6.4. Financial Overview
- 15.3.6.5. Strategic Overview
- 15.3.7. Teva Pharmaceuticals
- 15.3.7.1. Company Overview
- 15.3.7.2. Disease Type Portfolio
- 15.3.7.3. SWOT Analysis
- 15.3.7.4. Financial Overview
- 15.3.7.5. Strategic Overview
- 15.3.8. Cipla
- 15.3.8.1. Company Overview
- 15.3.8.2. Disease Type Portfolio
- 15.3.8.3. SWOT Analysis
- 15.3.8.4. Financial Overview
- 15.3.8.5. Strategic Overview
- 15.3.9. Liminal Biosciences
- 15.3.9.1. Company Overview
- 15.3.9.2. Disease Type Portfolio
- 15.3.9.3. SWOT Analysis
- 15.3.9.4. Financial Overview
- 15.3.9.5. Strategic Overview
- 15.3.10. Fibrogen
- 15.3.10.1. Company Overview
- 15.3.10.2. Disease Type Portfolio
- 15.3.10.3. SWOT Analysis
- 15.3.10.4. Financial Overview
- 15.3.10.5. Strategic Overview
- 15.3.11. PharmAkea Therapeutics
- 15.3.11.1. Company Overview
- 15.3.11.2. Disease Type Portfolio
- 15.3.11.3. SWOT Analysis
- 15.3.11.4. Financial Overview
- 15.3.11.5. Strategic Overview
- 15.3.12. IQVIA
- 15.3.12.1. Company Overview
- 15.3.12.2. Disease Type Portfolio
- 15.3.12.3. SWOT Analysis
- 15.3.12.4. Financial Overview
- 15.3.12.5. Strategic Overview
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook